Literature DB >> 18820127

90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.

Archie N Tse1, Tahir N Sheikh, Ho Alan, Ting-Chao Chou, Gary K Schwartz.   

Abstract

The G(2)/M cell cycle checkpoint is regulated by a multitude of signaling pathways after genotoxic stress. Herein, we report that treatment with the 90-kDa heat shock protein (Hsp90) molecular chaperone inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG) selectively abrogates the G(2)/M checkpoint induced by 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan, in p53-null compared with p53-intact HCT116 colon cancer cells. The basis for this selectivity can be explained in part by the lack of p21 induction in p53-null cells. In accord with published results, we could show that treatment with 17AAG resulted in depletion of Chk1, a known Hsp90 client protein. In addition, we observed a time- and dose-dependent decrease in Wee1 kinase level, a negative regulator of mitosis, after 17AAG treatment in gastrointestinal cancer cells. Depletion of Wee1 protein preceded mitotic entry induced by 17AAG, and this decrease could be partially rescued by cotreatment with a proteasome inhibitor. Coimmunoprecipitation experiments showed that Hsp90 and Wee1 interacted in whole cells, and 17AAG treatment decreased the degradative half-life of Wee1, indicating that Wee1 is another Hsp90 client in mammalian cells. Knockdown of Chk1 and Wee1 by short interfering RNA each resulted in abrogation of the G(2)/M checkpoint induced by SN-38. The combination of SN-38 and 17AAG was shown to be synergistic in p53-null but not in parental HCT116 cells by median effect/combination index analysis. Taken together, 17AAG specifically inhibits the G(2)/M checkpoint in p53-defective cells by down-regulation of two critical checkpoint kinases, Chk1 and Wee1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18820127      PMCID: PMC2685054          DOI: 10.1124/mol.108.050807

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  49 in total

Review 1.  Chaperoning steroid hormone action.

Authors:  Didier Picard
Journal:  Trends Endocrinol Metab       Date:  2006-06-27       Impact factor: 12.015

Review 2.  Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.

Authors:  Ting-Chao Chou
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

3.  CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.

Authors:  Archie N Tse; Katherine G Rendahl; Tahir Sheikh; Haider Cheema; Kim Aardalen; Millicent Embry; Sylvia Ma; Edward J Moler; Zhi Jie Ni; Daniel E Lopes de Menezes; Barbara Hibner; Thomas G Gesner; Gary K Schwartz
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

4.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage.

Authors:  F Bunz; A Dutriaux; C Lengauer; T Waldman; S Zhou; J P Brown; J M Sedivy; K W Kinzler; B Vogelstein
Journal:  Science       Date:  1998-11-20       Impact factor: 47.728

5.  The identification of Wos2, a p23 homologue that interacts with Wee1 and Cdc2 in the mitotic control of fission yeasts.

Authors:  M J Muñoz; E R Bejarano; R R Daga; J Jimenez
Journal:  Genetics       Date:  1999-12       Impact factor: 4.562

6.  Chaperoning checkpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperones.

Authors:  Sonnet J H Arlander; Sara J Felts; Jill M Wagner; Bridget Stensgard; David O Toft; Larry M Karnitz
Journal:  J Biol Chem       Date:  2005-12-05       Impact factor: 5.157

7.  Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells.

Authors:  M Motwani; T M Delohery; G K Schwartz
Journal:  Clin Cancer Res       Date:  1999-07       Impact factor: 12.531

8.  Human Myt1 is a cell cycle-regulated kinase that inhibits Cdc2 but not Cdk2 activity.

Authors:  R N Booher; P S Holman; A Fattaey
Journal:  J Biol Chem       Date:  1997-08-29       Impact factor: 5.157

9.  MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation.

Authors:  Isaac A Manke; Anhco Nguyen; Daniel Lim; Mary Q Stewart; Andrew E H Elia; Michael B Yaffe
Journal:  Mol Cell       Date:  2005-01-07       Impact factor: 17.970

Review 10.  Hsp90: a novel target for cancer therapy.

Authors:  David B Solit; Neal Rosen
Journal:  Curr Top Med Chem       Date:  2006       Impact factor: 3.295

View more
  18 in total

Review 1.  Macrocyclic inhibitors of hsp90.

Authors:  Victoria A Johnson; Erinprit K Singh; Lidia A Nazarova; Leslie D Alexander; Shelli R McAlpine
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

2.  Cooperative enhancement of radiosensitivity after combined treatment of 17-(allylamino)-17-demethoxygeldanamycin and celecoxib in human lung and colon cancer cell lines.

Authors:  Young-Mee Kim; Hongryull Pyo
Journal:  DNA Cell Biol       Date:  2011-08-10       Impact factor: 3.311

Review 3.  Molecular targets and mechanisms of radiosensitization using DNA damage response pathways.

Authors:  David R Raleigh; Daphne A Haas-Kogan
Journal:  Future Oncol       Date:  2013-02       Impact factor: 3.404

Review 4.  Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.

Authors:  Prithviraj Bose; Yun Dai; Steven Grant
Journal:  Pharmacol Ther       Date:  2014-04-24       Impact factor: 12.310

Review 5.  Targeting the dynamic HSP90 complex in cancer.

Authors:  Jane Trepel; Mehdi Mollapour; Giuseppe Giaccone; Len Neckers
Journal:  Nat Rev Cancer       Date:  2010-08       Impact factor: 60.716

Review 6.  Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy.

Authors:  Yingmei Wang; Ping Ji; Jinsong Liu; Russell R Broaddus; Fengxia Xue; Wei Zhang
Journal:  Mol Cancer       Date:  2009-02-13       Impact factor: 27.401

Review 7.  Update on Hsp90 inhibitors in clinical trial.

Authors:  Y S Kim; S V Alarcon; S Lee; M-J Lee; G Giaccone; L Neckers; J B Trepel
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

8.  A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.

Authors:  Archie N Tse; David S Klimstra; Mithat Gonen; Manish Shah; Tahir Sheikh; Rachel Sikorski; Richard Carvajal; Janet Mui; Caroll Tipian; Eileen O'Reilly; Ki Chung; Robert Maki; Robert Lefkowitz; Karen Brown; Katia Manova-Todorova; Nian Wu; Merrill J Egorin; David Kelsen; Gary K Schwartz
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

Review 9.  New insights into checkpoint kinase 1 in the DNA damage response signaling network.

Authors:  Yun Dai; Steven Grant
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

10.  Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin.

Authors:  Céline Jacquemont; Julian A Simon; Alan D D'Andrea; Toshiyasu Taniguchi
Journal:  Mol Cancer       Date:  2012-04-26       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.